9,569 research outputs found
Charlie May Simon materials
No full textThis collection contains materials relating to Arkansas author Charlie May Simon
Ageing and longevity genes in cardiovascular diseases
No full textOver the last century, Western societies experienced a demographic shift driven by increased lifespan and decreased fertility, resulting in the subversion of the world's demographic pyramid. In ageing societies, cardiovascular diseases are the major cause of morbidity and mortality, thus representing a major societal and economic burden. Indeed, ageing associates with the deterioration of a genetic network implicated in senescence and longevity, orchestrating deleterious cellular processes that converge in the structural and functional decline of both the myocardium and the vasculature. In this review, we revise a compendium of genes involved in these processes and delineate possible strategies to interfere with them. Dietary interventions (eg intermittent fasting) and sirtuin-activating compounds are among the most promising interventions shown to promote protective effects on the ageing cardiovascular system. We conclude that ageing and longevity genes modulate cardiovascular function by acting on deleterious downstream processes such as inflammation and oxidative stress, thus representing promising targets for the prevention and treatment of age-related cardiovascular dysfunction
Simon Nyakot
Full text linkabstract: Simon Nyakot left his village when he was six years old.
“Lost Boys Found” is an ongoing, interdisciplinary project that is collecting, recording and archiving the oral histories of the Lost Boys/Girls of Sudan. The collection is a work-in-progress, seeking to record the oral history of as many Lost Boys/Girls as are willing, and will be used in a future book.Age: 27Region: LakeThis picture and bio was donated to the Lost Boys Found project from The Arizona Lost Boys Cente
Cahiers Saint-Simon
No full texthttps://www.persee.fr/renderCollectionCover/simon.pngThe Société Saint-Simon was founded in 1972 in order to promote studies about the Duke of Saint-Simon (1675-1755), namely about the work, life, and thinking of the Mémoires’s author. Each year it issues a Cahier Saint-Simon. It contains the Acts of the annual Journée d’étude in Versailles, but also Notes and Documents, News of the Society and Book reviews.Fondée en 1972, la Société Saint-Simon a pour but de développer les études concernant l'oeuvre, la personne et la pensée du duc de Saint-Simon (1675-1755), l’auteur des Mémoires. Chaque année, paraît un numéro de Cahiers Saint-Simon contenant les actes de la journée annuelle de Versailles, ainsi que des Mélanges, des Notes et Documents et une Chronique bibliographique détaillée
Cahiers Saint-Simon
No full texthttps://www.persee.fr/renderCollectionCover/simon.pngThe Société Saint-Simon was founded in 1972 in order to promote studies about the Duke of Saint-Simon (1675-1755), namely about the work, life, and thinking of the Mémoires’s author. Each year it issues a Cahier Saint-Simon. It contains the Acts of the annual Journée d’étude in Versailles, but also Notes and Documents, News of the Society and Book reviews.Fondée en 1972, la Société Saint-Simon a pour but de développer les études concernant l'oeuvre, la personne et la pensée du duc de Saint-Simon (1675-1755), l’auteur des Mémoires. Chaque année, paraît un numéro de Cahiers Saint-Simon contenant les actes de la journée annuelle de Versailles, ainsi que des Mélanges, des Notes et Documents et une Chronique bibliographique détaillée
Simon Weir - The Sydney Surrealist
No full textExhibition catalogue of "Simon Weir - The Sydney Surrealist", Exhibition at Disorder Gallery, Darlinghurst NSW, Australia, in April 2024. The catalogue contains images of exhibited works and statements by the artist Simon Weir, the gallery Director Elliott Cole, and author and journalist Margie Smithurst
Joan Simon Correspondence
Full text linkEntries include a typed biographical letter from Simon in New York, explaining her relationship to Maine for the purposes of presentation to the Maine Author Collection
Colchicine in Coronary Artery Disease: Where Do We Stand?
No full textColchicine is an anti-inflammatory drug for different inflammatory conditions and is approved for secondary prevention of cardiovascular events in patients with coronary artery disease, mainly based on the results of the LODOCO2 and COLCOT trials. The recently published CLEAR SYNERGY trial reported neutral results for colchicine in patients with acute myocardial infarction undergoing percutaneous coronary intervention, challenging the previous reported benefits of colchicine. While colchicine appeared rather safe across the different studies, the variation in efficacy may suggest that the one-size-fits-all for the treatment of acute and chronic forms of coronary artery disease may not be appropriate, and that low-dose colchicine may be beneficial as an add-on therapy in patients who are stable or recovering from acute event, and not so helpful in patients with acute myocardial infarction already receiving intensive pharmaco-invasive therapies
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
No full textAn increasing number of individuals is at high risk of type 2 diabetes (T2D) and its cardiovascular complications, including heart failure (HF), chronic kidney disease (CKD), and premature death. The sodium-glucose cotransporter-2 (SGLT2) protein sits in the proximal tubule of human nephrons to regulate glucose reabsorption, and its inhibition by gliflozins represents the cornerstone of contemporary T2D and HF management. Herein, we aim to provide an updated view on the pleiotropy of gliflozins, provide mechanistic insights and delineate related cardiovascular (CV) benefits. By discussing contemporary evidence obtained in preclinical models and landmark randomized controlled trials, we move from bench to bedside across the broad spectrum of cardio- and cerebrovascular diseases. With robust trials confirming a reduction in major adverse CV events (MACE; composite endpoint of CV death, non-fatal myocardial infarction, and non-fatal stroke), SGLT2 inhibitors strongly mitigate the risk for heart failure hospitalization in diabetics and non-diabetics alike while conferring renoprotection in specific patient populations. Along four major pathophysiological axes (ie, at cardiac, vascular, renal, and systemic levels), we provide insights into key mechanisms that may underlie their beneficial effects, including gliflozins' role in the modulation of vascular inflammation, oxidative stress, cellular energy metabolism and housekeeping mechanisms. We also discuss how this drug class controls hyperglycaemia, ketogenesis, natriuresis, and hyperuricaemia, contributing to their pleiotropic effects. Finally, evolving data in the setting of cerebrovascular diseases and arrythmias are presented, and potential implications for future research and clinical practice are comprehensively reviewed
- …
